Cellectar Biosciences (CLRB) Payables (2010 - 2026)
Cellectar Biosciences (CLRB) posted Payables of $4.6 million for Q4 2025, down 3.45% sequentially from $4.8 million in Q3 2025, and down 50.02% YoY from $9.3 million in Q4 2024.
Cellectar Biosciences (CLRB) Payables (2010 - 2026) Analysis & Trends
Cellectar Biosciences has reported Payables for 16 years, with the latest figure at $4.6 million in Q4 2025.
- Quarterly Payables fell 50.02% year-over-year to $4.6 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $4.6 million (down 50.02% YoY) and the FY2025 annual result came in at $4.6 million, down 50.02% from the prior year.
- Payables eased to $4.6 million in Q4 2025 per CLRB's latest filing, from $4.8 million in the prior quarter.
- Over five years, Payables peaked at $29.8 million in Q3 2023 and troughed at $3.0 million in Q3 2021.
- A 5-year average of $11.0 million and a median of $7.1 million in 2022 frame the typical range for Payables.
- The sharpest annual moves came in 2023 and 2025: Payables surged 327.44% in 2023, then tumbled 79.17% in 2025.
- Over 5 years, Payables stood at $3.9 million in 2021, then jumped by 197.04% to $11.5 million in 2022, then soared by 120.95% to $25.3 million in 2023, then slumped by 63.23% to $9.3 million in 2024, then sank by 50.02% to $4.6 million in 2025.
- According to Business Quant data, Payables over the past three periods registered $4.6 million, $4.8 million, and $5.8 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 167.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 470.30 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 108.02 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 428.93 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 35.57 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 622.65 Mn |
| 10 | Cellectar Biosciences | 6.63 Mn | 6.63 Mn | - | 5.24 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 5.24 Mn |
| Dec 31, 2025 | 4.65 Mn |
| Sep 30, 2025 | 4.82 Mn |
| Jun 30, 2025 | 5.77 Mn |
| Mar 31, 2025 | 5.93 Mn |
| Dec 31, 2024 | 9.30 Mn |
| Sep 30, 2024 | 20.23 Mn |
| Jun 30, 2024 | 15.09 Mn |
| Mar 31, 2024 | 28.48 Mn |
| Dec 31, 2023 | 25.30 Mn |
| Sep 30, 2023 | 29.78 Mn |
| Jun 30, 2023 | 12.93 Mn |
| Mar 31, 2023 | 11.49 Mn |
| Dec 31, 2022 | 11.45 Mn |
| Sep 30, 2022 | 6.97 Mn |
| Jun 30, 2022 | 6.36 Mn |
| Mar 31, 2022 | 7.21 Mn |
| Dec 31, 2021 | 3.85 Mn |
| Sep 30, 2021 | 3.03 Mn |
| Jun 30, 2021 | 3.39 Mn |